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Summary Neuroblastoma cells express the polysiatylated form of the neural cell adhesion molecule (NCAM), which normally becomes
restricted to a few neural tissues after embryogenesis. In this study, we investigated serum levels of polysialylated NCAM in 14 children with
different grades and stages of neuroblastoma using an immunoluminescence assay, and compared the results to 269 healthy control
subjects. Simultaneousty, the polysialylated NCAM content of the tumours was determined by immunohistochemistry. Serum levels were
dramatcalty elevated (more than sixfold) in children with advanced stages and fatal courses of disease, whereas children with differentiated
tumour types and limited disease had low or normal levels. Serum concentrations correlated with the polysialylated NCAM content of the
tumours, and they decreased during successful therapy. We therefore suggest polysialylated NCAM to be a useful marker monitoring
childhood neuroblastoma.
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Polysialylated NCAM forms are transiently expressed in many
tissues during embryogenesis and become restricted to areas of
permanent neural plasticity in the adult brain (Rougon. 1993).
Some poorly differentiated tumours such as neuroblastoma. small-
cell lung cancer (Moolenaar et al. 1990) and multiple myeloma
(van Camp et al. 1990) re-express polysialylated NCAM forms.
The polysialic acid moiety has been shown to modulate the adhe-
sive functions of NCAM and other adhesion molecules and to be
relevant for an enhanced invasive and metastatic potential of
tumour cells (Yang et al. 1992). NCAM isoforms occur not only
membrane bound. but also as soluble molecules detectable in the
serum. Recently. it has been shown that the serum levels of poly-
sialylated NCAM are elevated in adult patients with small-cell
lung cancer (Jaques et al. 1993) and multiple myeloma (Kaiser et
al. 1994). high levels being associated with a poor prognosis
(Ledermann et al. 1994: Smith et al, 1996).
In this study. we investigated children with different histological
grades and stages of neuroblastoma and compared their serum
levels with those of 269 healthy control subjects. We present
evidence that serum polysialylated NCAM is a useful prognostic
marker for childhood neuroblastoma.
PATIENTS AND METHODS
Patients
Serum was collected from 14 children with different grades and
stages of neuroblastoma (Table 1). Simultaneously. histological
specimens were obtained for immunohistochemistry from all
patients but two (nos 1 and 11). Staging and histological grading
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were applied according to the international criteria set by Brodeur
et al (1988) and Hughes et al (1974). N-mwc gene amplification
was analysed by Southern blotting (performed at the Department
ofPaediatrics. University ofGie,en. Germany. by H Christiansen.
MD. and F. Lampert. MD: data shown with permission) in all
tumours but one (no. 1). The control group consisted of 269 chil-
dren with an age range from 1 day to 16 years affected by other
unrelated disorders. The project was approved by local ethics and
scientific committees.
Immunoluminescence assay
Serum samples were thawed and assayed for soluble polysialyl-
ated NCAM by a chemiluminescent immunoassay developed by
the Research Laboratories of Behring Diagnostics. Marburg.
Germany (Takamatsu et al. 1994). This assay system uses two
monoclonal antibodies (MAbs): the polysialic acid-specific anti-
body 735 (Frosch et al. 1985) for capture and the anti-NCAM anti-
body BW SCLC-1 for detection of soluble polysialylated NCAM.
MAb 735 specifically recognizes to a high degree a-2.8-linked
sialic acid polymers with oligosaccharide segments > 8 (Hvyrinen
et al. 1989). whereas MAb BW SCLC-1 specifically recognizes an
epitope on the third immunoglobulin-like domain of human
NCAM (M Eckhardt and R Gerardv Schahn. unpublished data).
An aliquot of 200 gl of Tris-buffered incubation medium
containing 0.5%c Tween 20 (pH 7.0) and 20gl of sample or stan-
dard was filled into tubes coated with MAb 735 and incubated for
1 h at room temperature. After washin. 200gl of MAb BW
SCLC-1 conjugated to an acridinium N-acylsulfonamide label was
added to each well. After incubation for 1 h at room temperature.
the reaction was terminated bv an additional washing cycle. The
chemiluminescence activitv was determined by using the BeriLux
Analyser 250 (Behringwerke. Marburg. Germany). The results
were expressed as kU 1-1 as previously descnrbed (Takamatsu et al.
1994). All measures were performed at least twice for internal
control.
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Table 1 Clinical data and serum polysialylated NCAM levels of 14 children with different grades and stages of neuroblastoma
No. Patient Histological Stageb N-myc Polysialylted Immunohisto- Clinical
gradea amplifiaion NCAM (kU [') chemistryc course
1 F. 2 months Neuroblastoma grade 3 4 nd 1377.0 ND Died of disease
2 F. 7 months Neuroblastoma grade 3 4 25 301.3 +++ Died of disease
3 M. 2 years 1 month Neuroblastoma grade 3 3 30 280.6 + Died of disease
4 F. 3 years 1 month Neuroblastoma grade 3 3 40 264.9 +++ Still under therapy
5 F. 6 months Neuroblastoma grade 3 4S 1 255.4 Disease-free 12 months
6 M. 6 months Neuroblastoma grade 3 1 1 221.7 Disease-free 9 months
7 F. 1 year 1 month Ganglioneuroblastoma grade 1a 2b 1 128.5 + Disease-free 9 months
8 F. 4 years 5 months Ganglioneuroblastoma grade 1a 3 1 90.2 + Disease-free 18 months
9 F. 4 months Neuroblastoma grade 3 1 1 52.9 +++ Disease-free 3 months
10 F. 1 month Neuroblastoma grade 3 1 1 51.5 ++ Disease-free 3 months
11 F. 4 years 3 months Ganglioneuroblastoma grade 1b 1 1 20.4 ND Disease-free 10 months
12 M. 8 years 2 months Ganglioneuroblastoma grade lb 1 1 15.0 - Disease-free 14 months
13 M. 1 year 2 months Ganglioneuroblastoma grade la 1 1 38.8 + Disease-free 16 months
14 F. 5 years 4 months Ganglioneuroblastoma grade 1b 1 1 30.7 - Disease-free 6 months
Bold numbers indicate pathological levels. F. female: M. male: ND. not done: -. no staining: +. few (<1/3 cells): ++. a lot (>113 cells): +++. most (>2/3 cells)
stained. aAccording to Hughes etal (1974). According to Brodeur eta) (1988). Immunoreactvity for polysiaylated NCAM expressed in tumour cells
stained/total tumour cells.
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Figure 1 Serm levels of oolysialylated NCAM in 269 healthy control
subjects. Mean value 26.8 kU V*. range 4.4-62.9 kU V .KU V were defined _
as descnibed previously (Takamatsu et al. 1994) - '
Figure 2 Lymnph node metastasis of patient no. 2 wth a neuroblastom
gradie 3. stage 4. Immunohistochlemical staining with MAb 735. shwowing
Immunohistochemistry ~~~~~~~~~~strong expression ofptolysialylated NCAM on the tumour cells. Arrowhis
indicates lymnphocytes. negative for polysialyated NCAM (original
x~ ~ ~ ~ ~ ~ ~ ~~~~~~~~anfcto x66)
Cr'-ostat sections 15 tm) of snap-frozen tumour specimens xw-ere mgiiain~6
further processed for iinmunohistochemistry using the APAAP
technique according to Cordell et al i1984i. Briefly, the slides
1erefixed in ice-cold acetone for 10 m and air dried. After-
preincubation xw-ith normal rabbit serum, the MAb 735 1Frosch et
al. 1 9R5 was added for 1 h at room temperature After 1 ashing.
the slides
ereincubated sithrabbit anti-mouse i6 munoglobulin E
ct
and the APAAP complex tku ice for 1 h each. Colourde- elopmente vas obtained preith Naphthol-AS-Biphosphate and Nea Fuchsin. . 4'
PositixFe reaction of the counterstained cells resulted in bright red -- ' no. 2 wh a neuroblastorn
staininga of the cygtoplasm. Controls included the omission of 4uhoec staining w MA 5 sw
primary andlor santibodies. preincubationoofnthe sections * Ehr tWZu cls Arwe
hith bacterophageendoneuraminidase for 2 h at 3TaC. rigch hasit l
beenshosta npretiouslg to recoanize specificalln and deg rad e pol
m ag-ico x66)
sialic acid (Ge rard m-Schahn et al. 1995. and staining withthe
NCAM-specific MAb Ul3A CrPatel et al. 1989\.
RESULTS
Fegure 3 Ganglioneuroblastoma of patient no. 12. Alost no reactivity
Meancalue ofthe 269 healthy control subjects x-as 26.8 kU 1-'. As poeysialyated NCAM in immunohistochemistryw5it MAb 735 (oniginal
shosin in Figure 1. the calues ranged from .4 to 62.9 kU1i. There magnification x66)
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Fgure 4 Follow-up polysaytaed NCAM levels during therapy: serum concentrabons decreased in patients with high serum levels initially and remained low in
patents with normal levels. Note variable scale
was no correlation with age or sex ofthe children. In this study. all
values above 60 kU 1- were designated as pathological.
The data of the neuroblastoma patients are summarized in Table
1: two infants (nos 1 and 2) with stage 4 disease and one child (no. 3)
with stage 3 disease had excessively high (1377.0kU 1-1) or high
serum levels (301.3, 280.6 kU 1-1 respectively). These children died
ofrapid tumour progression despite intensive chemotherapy. Patient
no. 4 with stage 3 disease and an initial serum level of264.9 kU 1-1 is
currently still receiving chemotherapy. One infant with stage 4S
disease (no. 5) had an initial serum level of 255.4 kU 1-1. Another
child (no. 6) with a large stage 1 neuroblastoma ofhistological grade
3 (tumour weight 200 g. the tumour was limited to one adrenal
gland) had a serum level of 221.7 kU 1-1. Two infants with small
adrenal stage 1 neuroblastoma (nos 9 and 10. tumour weight 9.5 g
and 4.5 respectively) had serum levels within normal ranges. Both
children with more differentiated tumour types but extensive disease
(nos 7 and 8) had moderately raised levels (128.5. 90.2 kU 1-'
respectively). All children with ganglioneuroblastoma stage (nos
11-14) had normal serum levels (20.4. 15.0, 38.8. 30.7 kU 1-'
respectively) at diagnosis.
N-mvc gene amplification (25- to 40-fold) was found in the
patients with the highest serum levels (nos 2-4). whereas no
amplification ofthe gene was found in the other tumours (Table 1).
Immunohistochemistry revealed high expression of polysialylated
NCAM in the tumour specimens of patients nos 2-6 and no. 9
(Table 1 and Figure 2). whereas the specimens ofthe other patients
had considerably smaller amounts ofpolysialylated NCAM (Table
1 and Figure 3).
As shown in Figure 4. eight children were available for follow-up
studies. In patients with high levels initially the serum concentrations
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of polysialylated NCAM decreased during therapy. After rewhing
normal levels, values remained normal during follow-up. In children
withlow levels initially, follow-up studies did notreveal anychanges
in serum concentraions.
DISCUSSION
In adult patients, serum polysialylated NCAM levels above
20 kU 1-' have been shown to be pathological (Jaques et al, 1993;
Kaiser et al, 1994). We found levels of up to 62.9 kU 1-l in
healthy children in whom the levels are on average higher (mean
26.8 kU 1-') than in adults. As the values cover a wide range (from
4.4 to 62.9 kU 1-1) we could not establish an age-dependent
decrease in serum polysialylated NCAM. This is in contrast to
previous findings in cerebrospinal fluid when a decrease was
observed during the first year oflife (Weisgerber et al, 1990).
The mechanism by which NCAM forms appear in the serum is
not known. The fact that there seems to be a relationship between
the serum levels and the estimated amount of polysialylated
NCAM-positive cells may indicate a constant release ofthis mole-
cule from the cell surface. PSA-NCAM is expressed also on
natural killer cells and a subset of T lymphocytes (van Riet et al.
1991). Theoretically. reactive shifts within these populations may
be of relevance to the PSA-NCAM serum level. However, the
serum levels of PSA-NCAM are low initially and during the
course of most other malignant and benign childhood diseases.
Moreover, we found a strong correlation between the levels of
PSA-NCAM and the number of viable cells in cultures of neuro-
blastoma cells, indicating that the molecule in factderives from the
tumour cells (unpublished observations).
In a recent study (Figarella-Branger et al, 1996), polysialylated
NCAM levels in cerebrospinal fluid were shown to correlate with
clinical stage and outcome of patients with medulloblastoma.
Our data show that polysialylated NCAM is a useful marker in the
far more easily accessible serum of children suffering from
neuroblastoma.
A reliable and widely accepted prognostic factor in childhood
neuroblastoma is amplification of the N-mvc gene in the tumour
(Brodeur et al, 1984). In our study. N-mc gene amplification was
found in the three children with the highest serum levels of poly-
sialylated NCAM, two of whom died subsequently ofprogressive
disease. In contrast, amplification was not present in the tumours
of the patients with moderately raised or normal serum levels.
However, two children with non-amplifying tumours had high
(>200 kU 1-') serum levels, one with stage 4S disease and one with
a large stage 1 adrenal tumour. Obviously, serum polysialylated
NCAM did not distinguish these children from the others with a
poor prognosis. As a consequence, it seems possible to speculate
that, rather than indicating a defined tumour stage, serum poly-
sialylated NCAM levels reflect the total amount of polysialylated
NCAM-positive tumour cells, which in turn represent the viable
tumour mass.
Polysialylation ofNCAM has previously been shown to modu-
late the adhesive functions of tumour cells and to enhance their
invasive and metastatic potential (Yang et al, 1992). Therefore, it
is conceivable that high serum levels of polysialylated NCAM
indicate more malignant tumour types. In our study, significantly
lower serum levels were found in children with differentiated
tumour types compared with undifferentiated tumours. In differen-
tiated ganglioneuroblastomas, pathological levels occurred only in
children with advanced stages of disease. Thus, serum polysialyl-
ated NCAM levels are influenced by both the tumour mass and
histological differentiation. Serum levels decreased during
successful therapy and remained low in patients during remission.
This indicates that soluble polysialylated NCAM may be a useful
marker for maintaining therapy in neuroblastoma patients.
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